Praful Ravi, MB, BChir, MRCP, discusses results from PSMAtrack, which assessed changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer. According to Ravi, ...
ctDNA-guided adjuvant atezolizumab for MIBC achieved improved DFS and OS versus placebo in ctDNA-positive patients, enabled by FDA-approved Signatera CDx companion diagnostic. Durvalumab plus BCG ...
In this episode of Pearls & Perspectives, Amy Pearlman, MD, speaks with Tom Riester of LTR Pharma about the development of a novel intranasal therapy for erectile dysfunction, exploring its potential ...
In “Perioperative Therapy Expansion in Cisplatin-Ineligible MIBC,” our panel explores how the treatment paradigm for muscle-invasive bladder cancer (MIBC) is rapidly evolving with the emergence of ...
Pedro C. Barata, MD, MSc, FACP, discusses preliminary findings from the phase 3 ProstACT Global study evaluating 177Lu-rosopatamab plus standard of care for patients with mCRPC. According to Barata, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results